Metsera (MTSR) Proxy Filing summary

Executive summary

• Special Meeting called to vote on a merger with Pfizer, making the company a wholly-owned subsidiary and delisting its stock from Nasdaq.

• Merger consideration per share: $47.50 in cash plus one contingent value right (CVR) for potential milestone payments.

• Board unanimously recommends voting FOR the merger and adjournment proposals.

• If the merger is not approved, the company remains independent and listed, but may owe a $190 million termination fee under certain conditions.

Voting matters and shareholder proposals

• Shareholders are asked to vote on: (1) adoption of the Merger Agreement, and (2) adjournment of the meeting if more votes are needed.

• Approval of the merger requires a majority of outstanding shares; adjournment requires a majority of votes cast.

• Major shareholders have entered into voting agreements to support the merger.

Board of directors and corporate governance

• Board conducted a thorough review of strategic alternatives, including negotiations with multiple potential acquirers.

• Board received fairness opinions from Goldman Sachs and Guggenheim Securities, both concluding the merger consideration is fair.

• Board may change its recommendation only under specific circumstances, such as a superior proposal or intervening event, following a defined process.